RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 Major CIED Infections Significantly Lower with Use of Antibacterial Envelope
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 12
SP 18
OP 19
DO 10.1177/155989771312008
UL http://mdc.sagepub.com/content/13/12/18.abstract
AB Infections associated with cardiovascular implantable electronic devices (CIEDs) cause substantial morbidity and mortality. The AIGISRx antibacterial envelope (ABE) for prophylaxis of CIED infections was approved by the Food and Drug Administration in 2008 for use with perioperative IV antibiotics. The AIGISRx Envelope for Prevention of Infection Following Replacement With an Implantable Cardioverter-Defibrillator (ICD) [CITADEL; NCT01043861] or Cardiac Resynchronization Therapy Device (CRT) [CENTURION; NCT01043705] trials prospectively evaluated the effectiveness of the ABE in patients implanted with a non-de novo single- or dual-chamber ICD (CITADEL) or non-de novo CRT (CENTURION) devices.